商品编号


4826-30-K



品牌


Trevigen



公司


Trevigen, Inc



公司分类


Apoptosis



Size

30 Samples

商品信息

Description

This kit allows the user to successfully label apoptotic cells, including endothelial and smooth muscle cells, throughout the vascular system. Similar to the CardioTACS? Kit, this kit is also based on DNA end-labeling using terminal deoxynucleotidyl transferase (TdT) and a modified nucleotide that is subsequently detected using our TACS Blue Label? detection system with Red Counterstain C. Specifically, VasoTACS? has been tested and optimized to help resolve the unique problems encountered when detecting apoptotic vascular cells.

FEATURES:


Performance tested on vascular tissues.

Includes both Proteinase K and exclusive Cytonin? non-enzymatic perme
ABI
lization reagents.

Helps resolve unique problems encountered when detecting apoptotic vascular cells.


APPLICATIONS:


In situ
detection of apoptosis in fixed frozen, paraffin embedded, or plastic embedded vascular cells and tissues.

Assists in the identification of apoptotic morphologies.



?





Catalog # 4826-30-K includes :



Catalog Number

Description

Qty



4800-30-01

Proteinase K

1



4800-30-06

Streptavidin-HRP

1



4800-30-11

TACS-Blue Label?

1



4800-30-12

Blue Strep-HRP Diluent

1



4800-30-15

TACS-Nuclease?

1



4800-30-16

TACS-Nuclease? Buffer

1



4800-30-19

Red Counterstain C

1



4810-30-02

TACS 2 TdT Labeling Buffer

1



4810-30-03

TACS 2 TdT Stop Buffer

1



4810-30-04

TACS 2 TdT dNTP

1



4810-30-05

TdT Enzyme

1



4810-30-14

50x Manganese Cation

1



4876-05-01

Cytonin?

1




?

Endothelial lipid phosphate phosphatase-3 deficiency that disrupts the endothelial barrier function is a modifier of cardiovascular development
Ishita Chatterjee, Jugajyoti Baruah, Erin E. Lurie, and Kishore K. Wary
Cardiovasc Res, May 2016; 10.1093/cvr/cvw090.
http://cardiovascres.oxfordjournals.org/cgi/content/abstract/cvw090v2

“Endothelial lipid phosphate phosphatase-3 deficiency that disrupts the endothelial barrier function is a modifier of cardiovascular
development”
Ishita Chatterjee, Jugajyoti Baruah, Erin E. Lurie, and Kishore K. Wary
Cardiovasc Res, Jul 2016; 111: 105 – 118
http://cardiovascres.oxfordjournals.org/cgi/content/abstract/111/1/105